Adjunctive Systemic Corticosteroids for Hospitalized Community-Acquired Pneumonia: Systematic Review and Meta-Analysis 2015 Update

Nobuyuki Horita1, Tatsuya Otsuka2, Shusaku Haranaga3, Ho Namkoong4, Makoto Miki5, Naoyuki Miyashita6, Futoshi Higa7, Hiroshi Takahashi8, Masahiro Yoshida9, Shigeru Kohno10 & Takeshi Kaneko1

Previous randomized controlled trials (RCTs) and meta-analyses evaluated the efficacy and safety of adjunctive corticosteroids for community-acquired pneumonia (CAP). However, the results from them had large discrepancies. The eligibility criteria for the current meta-analysis were original RCTs written in English as a full article that evaluated adjunctive systemic corticosteroids adding on antibiotic therapy targeting typical and/or atypical pathogen for treating hospitalized human CAP cases. Four investigators independently searched for eligible articles through PubMed, Embase, and Cochrane databases. Random model was used. The heterogeneity among original studies and subgroups was evaluated with the I² statistics. Of 54 articles that met the preliminary criteria, we found 10 eligible RCTs comprising 1780 cases. Our analyses revealed following pooled values by corticosteroids. OR for all-cause death: 0.80 (95% confidence interval (95% CI) 0.53–1.21) from all studies; 0.41 (95% CI 0.19–0.90) from severe-case subgroup; 0.21 (95% CI 0.0–0.74) from intensive care unit (ICU) subgroup. Length of ICU stay: −1.30 days (95% CI (−3.04)–(−0.44)). Length of hospital stay: −0.98 days (95% CI (−1.26)–(−0.71)). Length to clinical stability: −1.16 days (95% CI (−1.73)–(−0.58)). Serious complications do not seem to largely increase by steroids. In conclusion, adjunctive systemic corticosteroids for hospitalized patients with CAP seems preferred strategies.

Respiratory infection including pneumonia is the third-leading cause of death worldwide1–3. A majority of patients with pneumonia presents with community-acquired pneumonia (CAP). Despite recent advances in diagnostic methods and antibiotic treatment, the overall mortality rate of CAP remains approximately

1Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 2Department of Pulmonology, Tohoku Rosai Hospital, Sendai, Japan. 3Department of Infectious Diseases, Respiratory and Digestive Medicine, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan. 4Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. 5Department of Respiratory Medicine, Japanese Red Cross Sendai Hospital, Sendai Japan. 6Department of Internal Medicine I, Kawasaki Medical School, Okayama, Japan. 7National Hospital Organization Okinawa National Hospital, Okinawa, Japan. 8Division of Respiratory Medicine, Saka General Hospital, Miyagi, Japan. 9Department of Hemodialysis and Surgery, Chemotherapy Research Institute, International University of Health and Welfare, Ichikawa, Japan.
10Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Correspondence and requests for materials should be addressed to N.H. (email: nobuyuki_horita@yahoo.co.jp)
Although it had been considered that corticosteroids may exacerbate the control of infectious disease, the recent consensus is that adjunctive corticosteroids added to antibiotic treatment is a reasonable strategy when treating patients with critical infectious diseases namely bacterial meningitis, sepsis and septic shock. The therapeutic efficacy of corticosteroids may be based on down regulation of excessive inflammation via controlling cytokines. Similarly, corticosteroids attenuate the action of many cytokines involved in the inflammatory response associated with CAP. Thus, the use of adjunctive corticosteroids is an appealing option for CAP treatment and has been evaluated in many randomized controlled trials (RCTs) for decades. However, the results from previously reported RCTs that evaluated the impact of systemic corticosteroids for CAP had large discrepancies with each other. In addition, meta-analyses of these RCTs did not reach complete agreement (Table 1). Furthermore, a middle-scale and a large scale RCTs published in 2015 were not included in these published meta-analyses. Moreover, some recent studies were focused on the time to clinical stability, however, none of the previous meta-analyses evaluated the time to clinical stability. Therefore, we believe an updated meta-analysis is required. The aim of this study was to evaluate the efficacy and safety of adjunctive corticosteroids for patients with CAP.

### Methods

#### Study search.
Institutional review board approval and patient consent were not required because of the review nature of this study.

Four investigators independently searched for eligible articles as of March 2015 through PubMed, Embase, and Cochrane databases. One reviewer used the following search formula for PubMed: "(community acquired pneumonia) AND (RCT OR randomized) AND (steroid OR corticosteroid OR cortisol OR methylprednisolone OR prednisolone OR dexamethasone OR hydrocortisone)".

The eligibility criteria for the current meta-analysis were original RCTs written in English as a full article that evaluated adjunctive systemic corticosteroids adding on antibiotic therapy targeting typical and/or atypical pathogen for treating hospitalized human CAP cases. Any types, any doses, and any durations of systemic corticosteroids were allowed. Articles focusing on an immunocompromised host, inhaled corticosteroid, nosocomial pneumonia, child cases, or specified pathogens were excluded. Included articles had to evaluate at least one of the outcomes mentioned below.

#### Outcomes.
Mortality that can be expressed as an odds ratio (OR) was evaluated. If two or more types of mortality were described, the mortality of longer duration was selected. For example, 90-day mortality was preferred followed by 30-day, in-hospital, intensive care unit (ICU) mortality, in that order.

| Author, year | Severity and type of pneumonia | Number of studies | number of cases | Conclusion |
|--------------|--------------------------------|-------------------|----------------|------------|
| Salluh, 2008<sup>17</sup> | Severe CAP | 3 RCTs and 1 cohort study | 415 | Not recommending CS for severe CAP. |
| Siempos, 2008<sup>18</sup> | CAP with any severity (only studies for severe CAP were found) | 4 RCTs | 189 | Limited data suggested that CS lowers mortality and shortens length of hospital stay for severe CAP. |
| Chen, 2011<sup>19</sup> | Any type of pneumonia, including nosocomial and child pneumonia | 6 RCTs (2 for child, 1 for inhaled CS) | 437 | CS are generally beneficial for pneumonia. Evidence is lacking to make recommendation. |
| Nie, 2012<sup>20</sup> | CAP with any severity. | 9 RCTs | 1001 | CS is not recommended for CAP in general. However, it is possible that CS lower mortality from severe CAP and that CS > 6 d may be more beneficial than CS ≤ 5 d. |
| Cheng, 2013<sup>21</sup> | Severe CAP | 4 RCTs | 264 | Limited evidence suggests that CS lowers mortality from severe CAP. |
| Shafiq, 2013<sup>22</sup> | CAP requiring admission. | 8 RCTs | 1119 | CS shortens length of hospital stay. CS does not lower mortality. |
| Current study | CAP requiring admission. | 10 RCTs | 1780 | CS shortens length of hospital stay for CAP. CS shortens length to clinical stability for CAP. CS lowers mortality for CAP in intensive care unit. CS > 6 d is not more beneficial than CS ≤ 5 d. |

**Table 1.** Systematic reviews and meta-analyses evaluating adjunctive corticosteroids for community-acquired pneumonia. [ ]: reference number. RCT: randomized controlled trial. CS: corticosteroids. CAP: community-acquired pneumonia.
Length of ICU stay, length of hospital stay, and length to clinical stability in the form of a hazard ratio (HR) or mean difference were also meta-analyzed.

Statistics. If both an intention-to-treat analysis and per-protocol-analysis were conducted, we adopted the result from the intention-to-treat analysis. Throughout the meta-analyses random model, not fixed model, was used. If necessary, mean and standard deviation (SD) of length of ICU stay, length of hospital stay, and length to clinical stability were estimated from median, range, or interquartile range of them.

The heterogeneity among original studies and subgroups was evaluated with the I^2 statistics whereby I^2 = 0% indicates no heterogeneity, 0% < I^2 < 25% indicates the least heterogeneity, 25% ≤ I^2 < 50% indicates mild heterogeneity, 50% ≤ I^2 < 75% indicates moderate heterogeneity, and 75% ≤ I^2 indicates strong heterogeneity.

Results
Study search. Of 54 articles that met the preliminary criteria, we found 10 eligible RCTs (Fig. 1). These 10 RCTs include four single-facility trials and six multiple-facility trials. Concerning blinding, seven were blinded for both physicians and patients, one was blinded for only patients, and two were not blinded. Prednisolone (PSL), hydrocortisone (HC), methylprednisolone (mPSL), and dexamethasone (DEX) were administered for four, three, two, and one trial, respectively. One study used HC bolus only, while the others administered corticosteroids for three to nine days. The numbers of cases included in each study ranged from 30 to 785 with a median of 100. The average ages of patients in each study were early 60s for seven studies. In each study, 48–73% of cases were men (Table 2). Each study had a low or unclear risk of bias (Table 3).

Mortality. All included studies, except for one reported mortality. A report from Mikami did not report data concerning mortality. Moreover, no response to our e-mail inquiry was obtained from the author. Thus, data concerning mortality in this report was derived from a systematic review by Salluh et al.
Table 2. Characteristics of included randomized controlled trials. [ ]: reference number. ICU: intensive care unit. BTS: British Thoracic Society. ATS: American Thoracic Society. PORT PSL: prednisolone. mPSL: methylprednisolone. DEX: dexamethasone. HC: hydrocortisone d: day.

| Study            | Origin of report | blinding          | facility | Age criteria | Severity criteria | Steroid regimen | Antibiotics | Number of patients Steroid – Non-steroid = Total | Average age | Men% |
|------------------|------------------|------------------|----------|--------------|------------------|-----------------|-------------|-----------------------------------------------|-------------|------|
| Mchardy 1972     | Australia        | Not-blinded      | Single   | 12-          | not at risk of dying within 24 hour | PSL 20 mg/day for 7 d | Ampicillin 1 or 2 g/day | 40 + 86 = 126 | 61 | 48% |
| Marik 1993       | USA South Africa | Single-blinded   | Multi    | 18-70        | ICU, BTS criteria severe | HC 10 mg/kg bolus | Cefotaxime based regimen | 14 + 16 = 30 | 36 | NS |
| Confalonieri 2005 | Italy            | Double-blinded   | Multi    | 18-70        | ICU, ATS criteria severe | HC 200 mg bolus + 240 mg/day for 7 d | Based on guidelines | 23 + 23 = 46 | 64 | 70% |
| Mikami 2006      | Japan            | Not-blinded      | Single   | adult        | Moderate to severe. Not ventilated at admission | PSL 40 mg/day for 3 d | Amoxicillin and Moxifloxacin were preferred | 15 + 16 = 31 | 72 | 74% |
| Snijders 2010    | Netherlands      | Double-blinded   | Single   | 18-          | NS               | PSL 40 mg/day for 7 d | Amoxicillin and Moxifloxacin were preferred | 104 + 109 = 213 | 64 | 58% |
| Fernández-Serrano 2011 | Spain         | Double-blinded   | Single   | 18-75        | P/F ratio < 300, Not ventilated at admission | mPSL 200 mg bolus + 80 mg/day for 3 days + 40 mg/day for 3 days + 20 mg/day for 3 days. | Ceftriaxone + Levofloxacin | 22 + 23 = 45 | 64 | 67% |
| Meiysis 2011     | Netherlands      | Double-blinded   | Multi    | 18-          | Non-ICU          | DEX 5 mg/day for 4 d | Amoxicillin/ Clavulanate and Cephalosporin were preferred | 151 + 153 = 304 | 64 | 56% |
| Sabry 2011       | Egypt            | Double-blinded   | Multi    | adult        | ICU Ventilated   | HC 200 mg bolus + 300 mg/day for 7 d | NS | 40 + 40 = 80 | 62 | 73% |
| Blum 2015        | Switzerland      | Double-blinded   | Multi    | 18-          | NS               | PSL 50 mg/day for 7 d | Based on guidelines | 392 + 393 = 785 | 73 | 62% |
| Torres 2015      | Spain            | Double-blinded   | Multi    | 18-          | "ATS criteria severe" or "Pneumonia severity index = V and CRP > 150 mg/l" | mPSL 1 mg/kg/day for 5 d | Ceftriaxone + Levofloxacin or + Azithromycin were preferred | 61 + 59 = 120 | 65 | 62% |

Pooled OR for all-cause death by adjunctive corticosteroids estimated from the results of 10 RCTs was 0.80 (95% confidence interval (95% CI) 0.53–1.21, $P=0.29$. $I^2=0\%$, $P$ for heterogeneity = 0.46) (Fig. 2A).

Because previous meta-analyses suggested that systemic corticosteroids improve the mortality only for severe CAP\textsuperscript{17,20,21}, we performed a subgroup sensitive analysis dividing studies into those with severe case only and those not limited to severe cases. Previous meta-analyses used different criteria of “severe pneumonia”\textsuperscript{17,20,21}. Here, we selected studies that clearly indicated “severe CAP” in the title and/or abstract and studies limited to ICU cases. We observed a strong subgroup difference between the results from five trials not limited to severe cases and those from five trials limited to severe cases ($I^2=73.5\%$, $P$ for subgroup heterogeneity = 0.05) (Fig. 2A). Five RCTs limited to severe cases yielded a pooled OR of 0.41 (95% CI 0.19–0.90, $P=0.03$. $I^2=0\%$, $P$ for heterogeneity = 0.45) (Fig. 2A). In addition, we conducted another subgroup analysis dividing studies into those limited to ICU cases and those not limited to ICU cases. Again, we observed a strong subgroup difference ($I^2=79.7\%$, $P$ for subgroup heterogeneity = 0.03). Three RCTs limited to ICU cases yielded a pooled OR of 0.21 (95% CI 0.06–0.74, $P=0.01$. $I^2=0\%$, $P$ for heterogeneity = 0.43) (Fig. 2B).

Since Nie et al. reported that CS > 6 d was more beneficial than CS ≤ 5 d\textsuperscript{20}, we performed a sensitivity analysis. However, we could not find a significant subgroup OR difference between prolonged and short corticosteroids treatment for all-cause mortality. ($I^2=0\%$, $P$ for subgroup heterogeneity = 0.99) (Fig. 2C).

Using data from the five trials limited to severe cases, the pooled risk difference for mortality was $−0.10$ (95% CI $−(0.21)$–$(−0.00)$, $P=0.04$). This pooled difference of $−0.10$ was equivalent to a number needed to treat of 10 (Fig. 2D).

Length of ICU stay. A random-model meta-analysis using data from five RCTs indicated that length of ICU stay slightly favored the steroid arm but was not significantly different between the two arms with...
Table 3. Risk of bias. (a) Not centralized randomization. (b) Open-label study. (c) Open-label or single-blinded study. (d) 20% of cases were excluded after randomization and per-protocol analysis was conducted. (e) Mortality was not reported. (f) Considering relatively small sample size (<50), possible publication bias could not be denied. (g) Insufficient description of methods and results.

| Study Author, year | Randomization Method | Allocation Concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other bias | Overall risk |
|--------------------|----------------------|------------------------|---------------------------------------|-------------------------------|------------------------|-------------------|-----------|-------------|
| McHardy 1972       | Low                  | Unclear(a)              | Unclear(b)                            | High(c)                       | Low                    | Low               | Low       | Unclear     |
| Marik 1993         | Low                  | Unclear(a)              | Low                                   | High(c)                       | Low                    | Low               | Unclear   | Unclear     |
| Confalonieri 2005  | Low                  | Low                     | Low                                   | Low                           | Low                    | Unclear           | Low       | Low         |
| Mikami 2007        | Low                  | Unclear(a)              | Unclear(b)                            | High(c)                       | Low                    | Unclear           | Unclear   | Unclear     |
| Snijders 2010      | Low                  | Low                     | Low                                   | Low                           | Low                    | Low               | Low       | Low         |
| Fernández-S. 2011  | Low                  | Unclear(a)              | Low                                   | Unknown(d)                    | Low                    | Unclear           | Low       | Low         |
| Meijvis 2011       | Low                  | Low                     | Low                                   | Low                           | Low                    | Low               | Low       | Low         |
| Sabry 2011         | Low                  | Unclear(a)              | Low                                   | Low                           | Low                    | Low               | High(g)   | Unclear     |
| Blum 2015          | Low                  | Low                     | Low                                   | Low                           | Low                    | Low               | Low       | Low         |
| Torres 2015        | Low                  | Unclear(a)              | Low                                   | Low                           | Low                    | Low               | Low       | Low         |

A: OR for death. (Subgroup: severe cases or not)

B: OR for death. (Subgroup: ICU cases or not)

C: OR for death. (Subgroup: length of steroids treatment)

D: Risk difference for death. (Only studies limited to severe cases)

E: Mean difference for length of ICU stay.

F: Mean difference for length of hospital stay.

G: HR for hospital discharge.

H: Mean difference for length to clinical stability.

I: HR for clinical stability.

Figure 2. Forrest plots. OR: odds ratio. HR: hazard ratio. 95% CI: 95% confidence interval. M-H: Mantel-Haenszel. ICU: intensive care unit.
a mean difference of −1.30 days (95% CI (−3.04)−0.44, P = 0.14. I^2 = 25%, P for heterogeneity = 0.26) (Fig. 2E).

No study reported HR for length of ICU stay.

**Length of hospital stay.** Seven studies reported difference of length of hospital stay in days. Based on these data, the length of hospital stay was shorter in the steroid arm with a pooled mean difference of −0.98 (95% CI (−1.26)−(−0.71), P < 0.001. I^2 = 4%, P for heterogeneity = 0.39). We performed a sensitivity analysis comparing the result from a study by Blum et al. and those from the others because the study by Blum et al. had very large weight of 86.8%. However, there was no significant subgroup heterogeneity between them (I^2 = 0%, P for subgroup heterogeneity = 0.85) (Fig. 2F).

When evaluated using HR for hospital discharge, the length in hospital stay was also shorter in the steroid arm with a pooled HR of 1.23 (95% CI 1.07−1.41, P = 0.003. I^2 = 14%, P for heterogeneity = 0.32) (Fig. 2G).

**Length to clinical stability.** Length to clinical stability was evaluated in three recent studies. They yielded pooled difference of −1.16 days (95% CI (−1.73)−(−0.58), P < 0.001. I^2 = 43%, P for heterogeneity = 0.17) (Fig. 2H).

The same three studies yielded a pooled HR of 1.29 (95% CI 1.14−1.45, P < 0.001. I^2 = 0%, P for heterogeneity = 0.55) (Fig. 2I).

**Adverse effects.** In this systematic review, we noticed that some reports described adverse effects. However, these data were not suitable for qualitative meta-analysis due to discrepancy of descriptive method.

Confalonieri et al. reported that major complication (steroid: 6/23 vs. placebo 18/23, P < 0.001) and delayed septic shock (steroid: 0/23 vs. placebo: 10/23, P < 0.001) were less frequently observed in the steroid arm8. Mikami et al. reported no significant difference in deterioration of glucose intolerance, electrolyte abnormalities, nor other adverse effects was observed19. Snijders et al. revealed that the overall adverse effect was not different in two arms (steroid: 63/104 vs. placebo: 72/109, P = 0.41)25. Meijvis et al. reported that hyperglycemia was more common in the steroid arm (steroid: 67/151 vs. placebo: 35/153, P < 0.001) but that the requirement for glucose-lowering treatment and superinfection were not significantly different between arms15. Blum at al. wrote that overall adverse events were frequently observed in the steroid arm (steroid: 96/392 vs. placebo: 61/393, P < 0.001), and the difference was mainly attributed to the increase of hyperglycemia requiring new insulin (steroid: 76/392 vs. placebo: 43/393, P = 0.001)15. Torres et al. compared the incidence of six adverse effects including hyperglycemia but none differed significantly16.

In general, although patients in the steroid arm might have a higher risk for overall adverse events and hyperglycemia, serious complications do not seem to largely increase due to use of systemic steroids.

**Discussion**

This updated systematic review and meta-analysis had the largest sample size ever (Table 1). The key findings from this analysis are as follows: (i) corticosteroids shortens length of hospital stay for CAP, (ii) corticosteroids shortens length to clinical stability for CAP, and (iii) corticosteroids lowers mortality for severe CAP. Additionally, we revealed that the incidence of major complications was not greatly increased by systemic steroids, though quantitative synthesis was not feasible.

Inflammation is part of the complex biological response to harmful stimuli such as pathogens and damaged cells. This response is essential to control CAP. However, fulminant inflammation often results in organ failure. The rationale of using adjunctive systemic corticosteroids for CAP is to down-regulate excessive inflammation. Corticosteroids are very potent and by far the most frequently used type of immunosuppressant. The mechanism of corticosteroids is not fully clear; however, it is believed that corticosteroids switch off genes that encode pro-inflammatory cytokines and switch on genes that encode anti-inflammatory cytokines8. Based on our analysis, corticosteroids decreased mortality for severe/ICU CAP only. In this subgroup, merit of controlling systemic inflammation may outweigh the demerit of deteriorating innate body antibacterial action due to immunosuppressant.

Except for the OR for death, frequently used outcomes that we also evaluated in this study need be interpreted carefully. The length of hospital stay and ICU stay are often affected by non-pharmacological reasons, such as availability of ICU and non-ICU beds in a hospital. In this view, the time to clinical stability can evaluate more physiological aspects of a patient. However, some items included in the definition of clinical stability are known to be relieved by the administration of the systemic corticosteroids without direct relationship with the mortality26. For example, strong antipyretic effect of the corticosteroids obviously shortens the time to clinical stability. However, it is not clear whether the antipyretic effect can improve mortality and other outcomes. But then again, corticosteroids favored results for these uncertain outcomes, together with the decreased OR for death, made our results plausible.

The best corticosteroids regimen, for CAP is not clear. Nie et al. found that prolonged use of corticosteroids (>5 days) was associated with a greater benefit compared with short course corticosteroids (<5 days)20. However, this was not replicated in the current analysis. The length of the corticosteroids therapy used in the included trials was five days on average with a median of seven days (Table 2). Thus,
a 5–7 days treatment course seems reasonable for now. The best dosage of corticosteroids is also unclear. Most studies used HC 200–300 mg/day, PSL/mPSL 20–50 mg/day, or mPSL 1mg/kg/day (Table 2). Thus, a so-called low- or middle-dose of corticosteroids seems an acceptable choice in practice. Corticosteroids in these doses are also chosen for treatment of other common forms of critical systemic inflammatory disease such as acute exacerbation of chronic obstructive pulmonary disease27, acute respiratory distress syndrome29, and septic shock30.

Some studies that were not included in this study have also revealed the efficacy of systemic corticosteroids for CAP. García-Vidal et al. conducted a retrospective study with 308 severe CAP patients, which concluded that risk of death was reduced with adjusted OR of 0.28730. A cohort study in 2013 by Nagy et al. reported that the 5-day methylprednisolone therapy with imipenem was found to be effective in children with severe CAP31. Adjunctive systemic corticosteroids may be effective for CAP patients of any age.

Limitations of this study should be mentioned. First, we could not meta-analyze the data for adverse effects. Second, although four studies that evaluated the length of ICU stay constantly indicated the tendency of a steroid-favored outcome, these results did not reach statistical significance probably due to lack of power. Third, we could not infer the impact of corticosteroids for outpatients with CAP. Forth, the best corticosteroids regimen could not be clarified. Lastly, our analysis could not directly explain why the adjunctive corticosteroids have different impact for mild and severe CAP.

In conclusion, although further RCTs focusing on severe CAP are anticipated, adjunctive systemic corticosteroids for hospitalized patients with CAP seem preferred strategies because this treatment shortens the length of hospital stay and the length to clinical stability without increasing severe adverse effect. In addition, adjunctive systemic corticosteroids lowers the mortality of severe CAP cases. Prolonged use of corticosteroids (>5 days) was not more effective than a short-term use of corticosteroids (≤5 days). The best corticosteroids regimen is not clear, however, a middle dose of corticosteroids, for example PSL/mPSL 40 mg/day to 1 mg/kg/day for 5–7 days seems a reasonable choice.

References
1. Garnacho-Montero, J. et al. Determinants of outcome in patients with bacteraemic pneumococcal pneumonia: importance of early adequate treatment. Scand. J. Infect. Dis. 42, 185–92 (2010).
2. Musher, D. M. & Thorner, A. R. Community-acquired pneumonia. N. Engl. J. Med. 371, 1619–28 (2014).
3. Wunderink, R. G. & Waterer, G.W. Clinical practice. Community-acquired pneumonia. N. Engl. J. Med. 370, 543–51 (2014).
4. Brouwer, M. C. et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst. Rev. 6, CD004405 (2013).
5. Moran, J. L., Graham, P. L., Rockliff, S. & Bersten, A. D. Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective. Crit. Care. 14, R134 (2010).
6. Rhen, T. & Cidlowski, J. A. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N. Engl. J. Med. 353, 1711–23 (2005).
7. McHardy, V. U. & Schonell, M. E. Ampicillin dosage and use of prednisolone in treatment of pneumonia: co-operative controlled trial. Br. Med. J. 4, 569–73 (1972).
8. Mark, P., Kraus, P., Srirante, J., Havlik, I. & Lipman, J. W. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: a randomized controlled study. Chest. 104, 389–392 (1993).
9. Confalonieri, M. et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am. J. Respir. Crit. Care Med. 171, 242–8 (2005).
10. Mikami, K. et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung. 185, 249–55 (2007).
11. Snijders, D., Daniels, J. M., de Graaff, C. S., van der Werf, T. S. & Boersma, W. G. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am. J. Respir. Crit. Care Med. 181, 975–82 (2010).
12. Fernández-Serrano, S. et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit. Care. 15, R96 (2011).
13. Meijvis, S. C. et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 377, 2023–30 (2011).
14. Sabry, N. A. & Omar, E. E. D. Corticosteroids and ICU Course of Community Acquired Pneumonia in Egyptian Settings. Pharmacology & Pharmacy. 2, 73–81 (2011).
15. Blum, C. A. et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. pii:S0140-6736(14)62447-8 (2015).
16. Torres, A. et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomised clinical trial. JAMA. 313, 677–86 (2015).
17. Salluh, J. I. et al. Cortisol levels and adrenal response in severe community-acquired pneumonia: a systematic review of the literature. J. Crit. Care. 25, 541.e1–8 (2010).
18. Siempos, I. L., Vardakas, K. Z., Kopterides, P. & Falagas, M. E. Adjunctive therapies for community-acquired pneumonia: a systematic review. J. Antimicrob. Chemother. 62, 661–8 (2008).
19. Chen, Y., Li, K., Pu, H. & Wu, T. Corticosteroids for pneumonia. Cochrane Database Syst. Rev. 3, CD007720 (2011).
20. Nie, W., Zhang, Y., Cheng, J. & Xiu, Q. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS One. 7, e47926 (2012).
21. Cheng, L., Pan, Z. Y., Yang, J. & Gao, Y. D. Corticosteroid therapy for severe community-acquired pneumonia: a meta-analysis. Respir. Care. 59, 557–63 (2014).
22. Shafig, M., Mansoor, M. S., Khan, A. A., Sohail, M. R. & Murad, M. H. Adjuvant steroid therapy in community-acquired pneumonia: a systematic review and meta-analysis. J. Hosp. Med. 8, 68–75 (2013).
23. Higgins, P. J. & Green, S. Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). 2011. Available from: http://handbook.cochrane.org/ Accessed on March 25th (2015).
24. Hozo, S. P., Djulbegovic, B. & Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. BMC. Med. Res. Methodol. 2, 13 (2005).
25. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ. 327, 557–560 (2003).
26. Mandell L. A. et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 44, S27–72 (2007).
27. Leuppi, J. D. et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 309, 2223–31 (2013).
28. Tang, B. M., Craig, J. C., Eslick, G. D., Seppelt, I. & McLean, A. S. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit. Care Med. 37, 1594–603 (2009).
29. Dellinger, R. P. et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 36, 296–327 (2008).
30. Garcia-Vidal, C. et al. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur. Respir. J. 30, 951–6 (2007).
31. Bela, N. et al. Efficacy of methylprednisolone in children with severe community acquired pneumonia. Pediatric. Pulmonology. 48, 168–175 (2013).

Acknowledgements
This systematic review and meta-analysis was performed in the process of composing Japanese Respiratory Society Practical Guideline for Pneumonia. We would like to express our deepest appreciation for all the member of the Committee of the Guideline.

Author Contributions
H.N. served for analysis and drafting. H.N., O.T., S.H. and H.N. worked for study search. M.M., N.M., E.H., H.T. and T.K. served for analysis and interpretation of data. Y.M. is a statistical advisor. K.S. managed this study as the Chair of Japanese Respiratory Society Practical Guideline for Pneumonia. All authors critically revised the manuscript and finally approved the manuscript.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Horita, N. et al. Adjunctive Systemic Corticosteroids for Hospitalized Community-Acquired Pneumonia: Systematic Review and Meta-Analysis 2015 Update. Sci. Rep. 5, 14061; doi: 10.1038/srep14061 (2015).